Final analysis of PROpel supports abiraterone/olaparib as first-line option in mCRPC

I disagree with the headline but looks like this is the link that is postable. Final overall survival data for PROpel – (abi + olaparib in first line mCRPC). Not fully mature, trend towards improvement, greatest in patients with BRCA mutated disease with almost no difference in the patients with non BRCA mutated disease.

Read the full article here

Related Articles